Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. [electronic resource]
Producer: 20110310Description: 398-405 p. digitalISSN:- 1527-7755
- Ado-Trastuzumab Emtansine
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Breast Neoplasms -- drug therapy
- Disease-Free Survival
- Female
- Humans
- Immunotoxins -- adverse effects
- Kaplan-Meier Estimate
- Maytansine -- adverse effects
- Middle Aged
- RNA, Messenger -- analysis
- Receptor, ErbB-2 -- antagonists & inhibitors
- Time Factors
- Trastuzumab
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.